undamentalytics Newsletter
Sign in

Kyntra BIO, Inc. balance sheet

At the end of fiscal 2025, Kyntra BIO, Inc. had total assets of $120m, total liabilities of $115m and shareholders' equity of −$30.0m. It held $47.9m in cash against $0 of debt: net cash of $47.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents761651531746748912667817115682504851
Receivables—131510864284217165000
Inventory—————0717314017343
Total current assets—1982012677496907027554744933321979997
Total assets—484471470899881857827774610424215120101
Accounts payable—57669625263116548
Deferred revenue (current)—91381714071613132755
Total current liabilities—63676586891031632252742181332936
Total debt0000000000727300
Total liabilities—243274294351352322385545612586398115109
Shareholders' equity−61221178156528509516422209−21−204−226−30−30
Non-controlling interests and other (assets − liabilities − equity)—19191919191919202042423522
Net debt (negative = net cash)−76−165−153−174−674−89−126−678−171−156−1023−48−51
Shares outstanding———————————4m4m4m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KYNB vs OCGNKYNB vs TRDABOLT vs KYNB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kyntra BIO, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kyntra BIO, Inc.